Key facts
- This page summarizes Anthony G. Quinn's Form 4 filing for Aeglea BioTherapeutics, Inc. (SYRE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2022, 06:46.
Anthony G. Quinn - 16 Mar 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- SYRE
- Reported as of
- 16 Mar 2022
- Net transaction value
- +$187,705
- SEC form
- 4
- Accepted by SEC
- 18 Mar 2022, 06:46:58 UTC
- Prior SEC filing
- 15 Mar 2022
- Next SEC filing
- 13 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Kastenmayer, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anthony G. Quinn filed Form 4 for Aeglea BioTherapeutics, Inc. (SYRE) on 18 Mar 2022.
Change
- Previous filing in this sequence was filed on 15 Mar 2022.
- Current net transaction value: +$187,705.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AGLE
transaction
Common Stock
Purchase
- Transaction value
- $187,705
- Shares
- +80,079
- Change %
- +17%
- Price
- $2.34
- Shares after
- 550,540
- Date
- 16 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
AGLE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 266,295
- Date
- 16 Mar 2022
- Ownership
- By trusts
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.92 to $2.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Footnote F2
Includes 57,450 shares of common stock held by the Anthony G. Quinn Irrevocable Trust of 2018 and 208,845 shares of common stock held by the Quinn Family Irrevocable Trust of 2021(together, the "Trusts"). The Reporting Person's spouse is trustee of the Trusts.